GlassScriptPhysician profile
Yvette Mignon
NPI 1689743288
$21,828.89
in general payments reported to CMS, 2019-2025
40 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,719 · 2020: $9,360 · 2021: $5,643 · 2022: $1,091 · 2023: $1,320 · 2024: $1,064 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,902.29 | 2019-2021 | |
| Abbvie INC. | $5,890.65 | 2021-2025 | |
| Novo Nordisk INC | $743.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $587.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $451.09 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Indivior INC. | $356.68 | 2019-2025 | Sublocade |
| Sanofi-Aventis U.S. LLC | $343.02 | 2019-2023 | |
| Pfizer INC. | $317.69 | 2019-2024 | |
| Alkermes, INC. | $298.72 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $277.53 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.79 | 2019-2022 | |
| Glaxosmithkline, LLC. | $129.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $109.48 | 2019-2023 | Steglatro, Belsomra, Januvia |
| Janssen Pharmaceuticals, INC | $105.31 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.64 | 2024-2025 | Caplyta |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $88.52 | 2024 | Voquezna |
| Abbott Laboratories | $82.16 | 2023-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $70.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.35 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $61.14 | 2019-2023 | Rexulti |
| Amgen INC. | $57.78 | 2021-2025 | Evenity, Repatha, Otezla |
| Dexcom, INC. | $48.38 | 2022-2023 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $46.55 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.44 | 2022 | |
| Braeburn INC. | $40.91 | 2023-2024 | Brixadi |
| Blueprint Medicines Corporation | $38.60 | 2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $38.17 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $37.48 | 2021-2022 | |
| Genzyme Corporation | $35.21 | 2025 | |
| Supernus Pharmaceuticals, INC. | $24.95 | 2021 | |
| Beta Bionics, INC. | $24.64 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $23.49 | 2023 | Crysvita |
| Photonicare INC | $22.95 | 2023 | Otosight Middle Ear Scope |
| Radius Health, INC. | $20.50 | 2022 | |
| Astellas Pharma US INC | $18.46 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $17.79 | 2023 | Jornay Pm |
| Kvk-Tech, INC. | $16.94 | 2019-2022 | |
| Lundbeck LLC | $13.75 | 2024 | Rexulti |
| Almatica Pharma LLC | $13.51 | 2022 | |
| Assertio Therapeutics, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Mignon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.